Drug Trial Radar · NCT06672055
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,485
Planned (sponsor's estimate)
Start
Oct 8, 2024
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- VaxartIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
Conditions
- SARS-CoV2
- COVID-19
Interventions
VXA-CoV2-3.1Biological
Tablets for oral use.
COMIRNATY®Biological
Intramuscular (IM) injection.
VXA-CoV2-3.3Biological
Tablets for oral use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-vaccinationTime frame: Up to approximately Day 14
- KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 at 12 Months Post-vaccinationTime frame: Up to approximately 12 months
- XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccinationTime frame: Up to approximately Day 7
- XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccinationTime frame: Up to approximately Day 7
- XBB Sentinel Cohorts: Percentage of Participants who Experience Unsolicited Adverse Events (AEs) Through 30 Days Post-vaccinationTime frame: Up to approximately Day 30
- XBB Sentinel Cohorts: Percentage of Participants who Experience Treatment-emergent Adverse Events (TEAEs) Through 12 Months Post-vaccinationTime frame: Up to approximately 12 months
- XBB Sentinel Cohorts: Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccinationTime frame: Up to approximately Day 7
Locations
145 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group
Anniston, Alabama
Core Clinical Trials - Central Alabama Research LLC
Birmingham, Alabama
Coastal Clinical Research
Mobile, Alabama
Avacare - Lenzmeier Family Medicine
Glendale, Arizona
Desert Clinical Research
Mesa, Arizona
Velocity Clinical Research - MedPharmics - Phoenix
Phoenix, Arizona
Foothills Research Center
Phoenix, Arizona
Avacare (CCT) - Fiel Family & Sports Medicine
Tempe, Arizona
Baptist Health Center for Clinical Research - Little Rock
Little Rock, Arkansas
Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group
Cerritos, California
Velocity Clinical Research - Chula Vista (eStudySite - Chula Vista)
Chula Vista, California
Avacare - Benchmark Research - SOCAL-Colton
Colton, California
Altasciences Los Angeles (Formerly WCCT Global)
Cypress, California
Ark Clinical Research - Fountain Valley, CA
Fountain Valley, California
Velocity Clinical Research - San Diego (eStudySite - La Mesa)
La Mesa, California
Ark Clinical Research - Long Beach, CA
Long Beach, California
Velocity Clinical Research (National Research Institute) - Panorama City
Los Angeles, California
Northern California Research
Sacramento, California
Avacare - Benchmark Research - Sacramento
Sacramento, California
Velocity Clinical Research - Gardena
Santa Ana, California
Elite Research Network (ERN) - Legacy Clinical Trials
Colorado Springs, Colorado
Tekton Research - Fort Collins
Fort Collins, Colorado
Avacare - Critical Care, Pulmonary and Sleep Associates
Lakewood, Colorado
Tekton Research - Colorado - Longmont
Longmont, Colorado
Paradigm Clinical Research - Wheat Ridge
Wheat Ridge, Colorado
Stamford Therapeutics Consortium
Stamford, Connecticut
Chase Medical Research
Waterbury, Connecticut
Velocity Clinical Research - Washington DC
Washington D.C., District of Columbia
AMR - Miami (Clinical Research of South Florida)
Coral Gables, Florida
Universal Axon Clinical Research
Doral, Florida
Velocity Clinical Research - New Smyrna Beach
Edgewater, Florida
Fleming Island Center For Clinical Research
Fleming Island, Florida
AMR - Fort Myers - Clinical Physiology Associates
Fort Myers, Florida
Velocity Clinical Research - Hallandale Beach (MD Clinical)
Hallandale, Florida
ENCORE - Nature Coast Clinical Research Inverness
Inverness, Florida
ENCORE - Westside Center for Clinical Research
Jacksonville, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Headlands Research - JEM Research - Lake Worth
Lake Worth, Florida
Accel Research Sites - Lakeland
Lakeland, Florida
Accel Research Sites (ARS) - St. Petersburg - Largo
Largo, Florida
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.